Thank you ZPaul. I do not believe Ropes & Gray needed any
Thank you ZPaul. I do not believe Ropes & Gray needed any of the overwhelming recent events to prevail. I question whether SecureAuth/Knobbe Martins ever intended on winning this case or if they intention was to delay this until after their merger in December. Either way, your article puts front and center what SA stated about SFOR's patent:
Medical Treatment Patent Claims Held Patentable Subject Matter Under the Alice/Mayo Section 101 Test
Antoinette F. Konski
POSTED BY ANTOINETTE F. KONSKI ON 28 MAY 2018
b]The Federal Circuit’s Analysis – The Majority View[/b]
In analyzing patent-eligibility under Section 101, the Federal Circuit cited the two-part framework established by the U.S. Supreme Court as recited in Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014) (“Alice”). Step one of the test requires a determination “whether the claims at issue are directed to one of the patent-ineligible concepts of laws of nature, natural phenomena and abstract ideas.” Slip Op. at 27-28. If the claims are found not to be directed to a patent-ineligible concept, the court need not proceed to step 2 of the analysis.
The Federal Circuit determined that the challenged claims were not directed to patent-ineligible subject matter under step 1 of the two-part Alice/Mayo test. The Federal Circuit focused on the treatment element of the claims and noted that unlike the challenged Mayo claims, the ‘610 Patent claims are directed to a novel treatment method. The Mayo claims, in contrast, were directed to a diagnostic method based on the “‘relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of thiopurine drug will prove ineffective or cause harm.’” Slip Op. at 29
SecureAuth called Strikeforce's patent "abstract" even though numerous OOBA methods were included. The patent they have is the strongest patent under United States law...'a utility patent'...SFOR's is not a process patent. Additionally, many folks mat not be aware but Strikeforce was given 100% eligibility under their patent. Patents can be awarded with partial eligibility percentages.
The PTAB (TWICE), Microsoft as well as the other infringers never thought of Alice 35/101 to discredit SFOR's utility patent as not-inventive. Why? Because they are inventive or else they would have since Alice 35/101 has been around since 2014. Ironically enough, SFOR has had multiple utility patents for OOBA & MFA for several years now without challenge.
SecureAuth, I believe the final nail in your downfall will start on Monday and end days later!
9
Zerify Inc (ZRFY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...
Continue Reading
Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....
Continue Reading
Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...
Continue Reading
AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...
Continue Reading
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
Continue Reading
A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...
Continue Reading
A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...
Continue Reading
Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...
Continue Reading
Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...
Continue Reading
The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...
Continue Reading
Top 5 Most Recently Viewed Articles
Introduction to the Share Buy-back Program In a recent announcement, Genmab A/S (NASDAQ: GMAB) revealed that it has initiated an ambitious share buy-back program. This initiative aims to repurchase up to 2.2 million shares, which is a strategic step not just to reduce capital but also to fulfill commitments under the Restricted Stock Unit program. The company anticipates...
Continue Reading
Allego Appoints Holger Riemenschneider as Chief Technology Officer Allego N.V. (NASDAQ: ALGO) has recently appointed Holger Riemenschneider as its Chief Technology Officer. This move is a significant step for the company, which has rapidly established itself as a leading name in the electric vehicle (EV) charging industry. With Holger on board, Allego is looking to...
Continue Reading
Understanding the Semiconductor Fabrication Software Market The Semiconductor Fabrication Software market is on the brink of significant transformation, with projections indicating a remarkable growth of approximately USD 984.91 million from 2024 to 2028. This growth is primarily fueled by the rising complexity of semiconductor designs in conjunction with the impact of...
Continue Reading
Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...
Continue Reading
Introduction to Eli Lilly's Breast Cancer Initiatives At the upcoming San Antonio Breast Cancer Symposium (SABCS), Eli Lilly and Company (NYSE: LLY) is set to unveil groundbreaking data that enhances its portfolio in breast oncology. The symposium, running from December 9 to 12, serves as a platform for Lilly to highlight advancements in treatments for hormone...
Continue Reading